secwatch.observer — SEC 8-K summary
======================================

Issuer:     Century Therapeutics, Inc. (IPSC)
CIK:        0001850119
Form:       8-K
Filed at:   2026-06-08T20:10:52+00:00
Accession:  0001104659-26-071383
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Century Therapeutics presents preclinical data for CNTY-813; glucose control >8 months, IND on track for Q4 2026
--------------------------------------------------------------------------------

- CNTY-813 maintained glucose control for >8 months in diabetic mouse models without immunosuppression.
- No tumorigenesis observed in >140 mice with >1 billion cells infused over 3 months follow-up.
- Allo-Evasion 5.0 edits provided protection from NK cells, antibody-mediated phagocytosis, and maintained insulin secretion in humanized mouse model.
- Phase 1 manufacturing process established; consistent product quality across 11 samples from GMP Master Cell Bank.
- IND submission on track for Q4 2026; initial clinical data expected in 2H 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1850119/000110465926071383/0001104659-26-071383-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1850119/000110465926071383/tm2617028d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-071383

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer